\-\ Texto\\:\\ \ \(0\)\
\-\ not\\ available\\.\ \(14\)\
\-\ home\\ exercise\\,\\ physical\\ therapy\\,\\ oral\\ bisphosphonates\\,\\ calcitonin\\,\\ nsaids\\,\\ and\\ analgesics\\ are\\ the\\ mainstays\\ of\\ treatment\\.\\ \\ untreated\\ patients\\ should\\ get\\ alkaline\\ phosphatase\\ levels\\ and\\ radiographs\\ annually\\ while\\ treated\\ patients\\ should\\ get\\ alkaline\\ phosphatase\\ levels\\ every\\ 3\\-4\\ months\\ with\\ radiographs\\ annually\\.\ \(0\)\
\-\ ap\\ pelvis\\:\\ \\ coarsened\\ and\\ thickened\\ trabeculae\\ along\\ the\\ right\\ femoral\\ neck\\ and\\ greater\\ trochanter\\.\ \(0\)\
\-\ axial\\ ct\\ images\\ through\\ the\\ right\\ hip\\ and\\ pelvis\\:\\ \\ thickened\\ trabecular\\ markings\\ with\\ thickening\\ of\\ cortical\\ bone\\ along\\ the\\ right\\ femoral\\ neck\\ and\\ greater\\ trochanter\\.\\ \\ areas\\ of\\ increased\\ sclerosis\\ are\\ also\\ present\\ along\\ the\\ right\\ femoral\\ neck\\ and\\ greater\\ trochanter\\.\ \(0\)\
\-\ paget\\ disease\\ of\\ bone\ \(0\)\
\-\ paget\\'s\\ disease\ \(1\)\
\-\ osteosclerotic\\ bone\\ metastases\ \(0\)\
\-\ 62\\ y\\.o\\.\\ woman\\ for\\ metastatic\\ skeletal\\ survey\\ for\\ paget\\ disease\\.\ \(0\)\
\-\ the\\ patient\\ in\\ this\\ case\\ is\\ over\\ 40\\ years\\ of\\ age\\ and\\ paget\\ disease\\ of\\ bone\\ affects\\ approximately\\ 3\\-4\\%\\ of\\ the\\ population\\ over\\ 40\\ years\\ of\\ age\\.\\ \\ the\\ proximal\\ femur\\ was\\ affected\\ in\\ this\\ patient\\.\\ \\ the\\ pelvis\\ is\\ affected\\ in\\ 30\\-75\\%\\ of\\ cases\\ while\\ the\\ proximal\\ long\\ bones\\ are\\ affected\\ in\\ 25\\-30\\%\\ of\\ cases\\.\\ other\\ frequent\\ sites\\ of\\ involvement\\ include\\ the\\ skull\\ \\(25\\-65\\%\\ of\\ cases\\)\\ and\\ spine\\ \\(30\\-75\\%\\)\\.\\ \\ pelvic\\ involvement\\ is\\ more\\ often\\ asymmetric\\ than\\ symmetric\\,\\ and\\ appendicular\\ involvement\\ is\\ frequently\\ unilateral\\ as\\ in\\ this\\ case\\.\ \(0\)\
\-\ the\\ early\\ phase\\ of\\ paget\\ disease\\ is\\ characterized\\ by\\ osteolysis\\ on\\ radiographs\\.\\ \\ when\\ this\\ occurs\\ in\\ the\\ skull\\,\\ it\\ is\\ referred\\ as\\ osteoporosis\\ circumscripta\\.\\ \\ paget\\ disease\\ usually\\ affects\\ the\\ inner\\ table\\ of\\ the\\ skull\\ more\\ than\\ the\\ outer\\ table\\.\\ \\ this\\ is\\ in\\ contradistinction\\ to\\ fibrous\\ dysplasia\\ thataffects\\ the\\ outer\\ table\\ more\\ than\\ the\\ inner\\ table\\.\\ \\ in\\ long\\ bones\\,\\ osteolysis\\ begins\\ as\\ a\\ subchondral\\ lucency\\ likened\\ to\\ a\\ blade\\ of\\ grass\\ or\\ flame\\.\ \(0\)\
\-\ the\\ next\\ phase\\ of\\ paget\\ disease\\ is\\ the\\ mixed\\ phase\\.\\ \\ the\\ characteristic\\ manifestations\\ are\\ coarsening\\ and\\ thickening\\ of\\ the\\ trabecular\\ pattern\\ and\\ cortex\\.\\ \\ paget\\ disease\\ of\\ the\\ pelvis\\ usually\\ manifests\\ with\\ cortical\\ thickening\\ and\\ sclerosis\\ of\\ the\\ iliopectineal\\ and\\ ischiopubic\\ lines\\.\\ \\ the\\ findings\\ are\\ often\\ asymmetric\\ and\\ more\\ commonly\\ seen\\ on\\ the\\ right\\ side\\.\\ \\ within\\ the\\ spine\\,\\ osteoblastic\\ activity\\ is\\ seen\\ on\\ all\\ four\\ margins\\ of\\ the\\ vertebral\\ body\\ with\\ a\\ \\‚\\Ä\\úpicture\\ frame\\ appearance\\‚\\Ä\\ù\\ unlike\\ the\\ rugger\\ jersey\\ vertebrae\\ in\\ renal\\ osteodystrophy\\ which\\ only\\ involves\\ only\\ the\\ superior\\ and\\ inferior\\ endplates\\.\ \(0\)\
\-\ the\\ blastic\\ phase\\ is\\ the\\ next\\ phase\\ of\\ paget\\ disease\\.\\ \\ in\\ the\\ long\\ bones\\ and\\ pelvis\\,\\ areas\\ of\\ sclerosis\\ may\\ develop\\ and\\ can\\ be\\ extensive\\ obliterating\\ areas\\ of\\ previous\\ trabecular\\ thickening\\.\\ \\ bone\\ enlargement\\ is\\ common\\ in\\ this\\ phase\\.\\ \\ the\\ skull\\ can\\ have\\ a\\ \\‚\\Ä\\úcotton\\ wool\\‚\\Ä\\ù\\ appearance\\ while\\ the\\ spine\\ can\\ show\\ an\\ ivory\\ vertebral\\ body\\ on\\ radiography\\.\ \(0\)\
\-\ bone\\ scintigraphy\\ typically\\ demonstrates\\ marked\\ increased\\ uptake\\ of\\ radionuclide\\ in\\ all\\ phases\\ of\\ the\\ disease\\.\\ \\ in\\ the\\ quiescent\\ late\\ phase\\ of\\ the\\ disease\\,\\ radionuclide\\ activity\\ may\\ be\\ normal\\ with\\ persistent\\ abnormalities\\ seen\\ on\\ radiographs\\.\\ \\ patients\\ with\\ normal\\ bone\\ scans\\ and\\ abnormal\\ radiographic\\ findings\\ are\\ almost\\ always\\ asymptomatic\\ with\\ regard\\ to\\ paget\\ disease\\.\ \(0\)\
\-\ ct\\ may\\ show\\ areas\\ of\\ lysis\\ with\\ loss\\ of\\ normal\\ trabeculae\\.\\ \\ cortical\\ and\\ trabecular\\ thickening\\ are\\ well\\ demonstrated\\ as\\ well\\.\\ \\ areas\\ of\\ sclerosis\\ are\\ also\\ seen\\ in\\ the\\ blastic\\ phase\\.\ \(0\)\
\-\ mri\\ often\\ shows\\ maintenance\\ of\\ the\\ yellow\\ marrow\\.\\ \\ bone\\ enlargement\\ as\\ well\\ as\\ trabecular\\ and\\ cortical\\ thickening\\ have\\ low\\ signal\\ on\\ all\\ mr\\ pulse\\ sequences\\.\\ \\ \\ in\\ the\\ lytic\\ or\\ mixed\\ active\\ phase\\,\\ the\\ marrow\\ has\\ decreased\\ signal\\ intensity\\ on\\ t1\\ and\\ heterogeneous\\ high\\ signal\\ intensity\\ on\\ t2\\.\\ \\ the\\ increased\\ blood\\ flow\\ in\\ paget\\ disease\\ is\\ reflected\\ as\\ increased\\ enhancement\\ with\\ gadolinium\\.\ \(0\)\
\-\ complications\\ from\\ paget\\ disease\\ include\\ osseous\\ weakening\\ \\(deformity\\ and\\ fracture\\)\\,\\ arthritis\\,\\ neurologic\\ symptoms\\,\\ and\\ sarcomatous\\ transformation\\ which\\ occurs\\ in\\ 1\\%\\ of\\ cases\\.\\ \\ sarcomatous\\ transformation\\ is\\ seen\\ on\\ images\\ as\\ focal\\ bone\\ destruction\\ extending\\ through\\ the\\ cortex\\ with\\ an\\ associated\\ soft\\ tissue\\ mass\\.\\ \ \(0\)\
\-\ references\\:\ \(0\)\
\-\ 1\\.\\ \\ manaster\\ bj\\,\\ disler\\ dg\\,\\ may\\ da\\.\\ muskuloskeletal\\ imaging\\:\\ \\ the\\ requisites\\.\\ 2nd\\ ed\\.\\ philadelphia\\,\\ pa\\:\\ mosby\\,\\ inc\\.\\ 2002\\:\\ 416\\-417\\.\\ \ \(0\)\
\-\ 2\\.\\ \\ resnick\\ d\\.\\ \\ diagnosis\\ of\\ bone\\ and\\ joint\\ disorders\\.\\ \\ 4th\\ ed\\.\\ \\ philadelphia\\,\\ pa\\:\\ w\\.b\\.\\ saunders\\ company\\ 2002\\:\\ 1947\\-1995\\.\ \(0\)\
\-\ 3\\.\\ \\ smith\\ se\\,\\ et\\ al\\.\\ \\ from\\ the\\ archives\\ of\\ the\\ afip\\:\\ \\ radiologic\\ spectrum\\ of\\ paget\\ disease\\ of\\ bone\\ and\\ its\\ complications\\ with\\ pathologic\\ correlation\\.\\ \\ radiographics\\ 2002\\;\\ 22\\:1191\\-1216\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ paget\\:\\ 0\\.38687986101133537\ \(0\)\
\-\ the\\:\\ 0\\.28144273636597533\ \(0\)\
\-\ phase\\:\\ 0\\.23111688446738318\ \(0\)\
\-\ of\\:\\ 0\\.20555093724400417\ \(0\)\
\-\ disease\\:\\ 0\\.18895890080169284\ \(0\)\
\-\ bone\\:\\ 0\\.18012013744272443\ \(0\)\
\-\ trabecular\\:\\ 0\\.16962240438577833\ \(0\)\
\-\ and\\:\\ 0\\.16123281672521259\ \(0\)\
\-\ in\\:\\ 0\\.1269150301420339\ \(0\)\
\-\ table\\:\\ 0\\.12340946864436057\ \(0\)\
\-\ thickening\\:\\ 0\\.12249902831746326\ \(0\)\
\-\ trochanter\\:\\ 0\\.11570002729598927\ \(0\)\
\-\ is\\:\\ 0\\.10684083806500198\ \(0\)\
\-\ pelvis\\:\\ 0\\.10494694890544931\ \(0\)\
\-\ areas\\:\\ 0\\.10187458029621406\ \(0\)\
\-\ skull\\:\\ 0\\.09739640045491893\ \(0\)\
\-\ as\\:\\ 0\\.09644963782724748\ \(0\)\
\-\ are\\:\\ 0\\.09110036809900576\ \(0\)\
\-\ cortical\\:\\ 0\\.08618163820358794\ \(0\)\
\-\ 2002\\:\\ 0\\.08615772093408021\ \(0\)\
\-\ sclerosis\\:\\ 0\\.08550274860231774\ \(0\)\
\-\ on\\:\\ 0\\.08157264595622067\ \(0\)\
\-\ cases\\:\\ 0\\.08074027118047074\ \(0\)\
\-\ annually\\:\\ 0\\.07905171639266398\ \(0\)\
\-\ sarcomatous\\:\\ 0\\.07905171639266398\ \(0\)\
\-\ blastic\\:\\ 0\\.07804887447345761\ \(0\)\
\-\ radiographs\\:\\ 0\\.07785714323188174\ \(0\)\
\-\ affected\\:\\ 0\\.07404827525711208\ \(0\)\
\-\ osteolysis\\:\\ 0\\.07346851158943304\ \(0\)\
\-\ radionuclide\\:\\ 0\\.07346851158943304\ \(0\)\
\-\ bones\\:\\ 0\\.07244185788312324\ \(0\)\
\-\ trabeculae\\:\\ 0\\.07229820921871162\ \(0\)\
\-\ seen\\:\\ 0\\.07064304381032029\ \(0\)\
\-\ phosphatase\\:\\ 0\\.06899794319317734\ \(0\)\
\-\ alkaline\\:\\ 0\\.06749225382220678\ \(0\)\
\-\ femoral\\:\\ 0\\.06691467793501388\ \(0\)\
\-\ greater\\:\\ 0\\.0663278886270666\ \(0\)\
\-\ more\\:\\ 0\\.06591546980327277\ \(0\)\
\-\ get\\:\\ 0\\.06528560034386033\ \(0\)\
\-\ involvement\\:\\ 0\\.06516237118671918\ \(0\)\
\-\ increased\\:\\ 0\\.06491258443263899\ \(0\)\
\-\ with\\:\\ 0\\.0646403226480086\ \(0\)\
\-\ this\\:\\ 0\\.06187248811751329\ \(0\)\
\-\ affects\\:\\ 0\\.06150431157152504\ \(0\)\
\-\ transformation\\:\\ 0\\.06130763526074216\ \(0\)\
\-\ philadelphia\\:\\ 0\\.060738746648254426\ \(0\)\
\-\ may\\:\\ 0\\.06040852771858268\ \(0\)\
\-\ along\\:\\ 0\\.060317267003567425\ \(0\)\
\-\ long\\:\\ 0\\.059699767633441925\ \(0\)\
\-\ spine\\:\\ 0\\.059474295021599635\ \(0\)\
\-\ often\\:\\ 0\\.058745167016881976\ \(0\)\
\-\ inner\\:\\ 0\\.05872848708623385\ \(0\)\
\-\ while\\:\\ 0\\.05818518581709215\ \(0\)\
\-\ outer\\:\\ 0\\.05771179147671753\ \(0\)\
\-\ next\\:\\ 0\\.056050355338174526\ \(0\)\
\-\ neck\\:\\ 0\\.05507440472820363\ \(0\)\
\-\ asymmetric\\:\\ 0\\.054014426389745115\ \(0\)\
\-\ all\\:\\ 0\\.05359325932926148\ \(0\)\
\-\ than\\:\\ 0\\.05103596658497308\ \(0\)\
\-\ signal\\:\\ 0\\.05103596658497308\ \(0\)\
\-\ patients\\:\\ 0\\.050647314033624664\ \(0\)\
\-\ thickened\\:\\ 0\\.050628327948453546\ \(0\)\
\-\ marrow\\:\\ 0\\.04987888090867578\ \(0\)\
\-\ right\\:\\ 0\\.04974828959288428\ \(0\)\
\-\ mixed\\:\\ 0\\.04968342247812696\ \(0\)\
\-\ cortex\\:\\ 0\\.048876038989469406\ \(0\)\
\-\ ed\\:\\ 0\\.04801546069513172\ \(0\)\
\-\ thataffects\\:\\ 0\\.047993011486056884\ \(0\)\
\-\ ischiopubic\\:\\ 0\\.047993011486056884\ \(0\)\
\-\ levels\\:\\ 0\\.047583733416087404\ \(0\)\
\-\ occurs\\:\\ 0\\.04732263127698174\ \(0\)\
\-\ can\\:\\ 0\\.04724537251059658\ \(0\)\
\-\ pa\\:\\ 0\\.046060434206244213\ \(0\)\
\-\ enlargement\\:\\ 0\\.04601478608141265\ \(0\)\
\-\ complications\\:\\ 0\\.0459693351413202\ \(0\)\
\-\ rugger\\:\\ 0\\.04585988463632681\ \(0\)\
\-\ wool\\:\\ 0\\.04585988463632681\ \(0\)\
\-\ vertebral\\:\\ 0\\.04583414857586437\ \(0\)\
\-\ mainstays\\:\\ 0\\.04434640705055836\ \(0\)\
\-\ iliopectineal\\:\\ 0\\.04434640705055836\ \(0\)\
\-\ jersey\\:\\ 0\\.04434640705055836\ \(0\)\
\-\ cotton\\:\\ 0\\.04434640705055836\ \(0\)\
\-\ quiescent\\:\\ 0\\.04434640705055836\ \(0\)\
\-\ reflected\\:\\ 0\\.04434640705055836\ \(0\)\
\-\ 40\\:\\ 0\\.04414206934423975\ \(0\)\
\-\ activity\\:\\ 0\\.04406609878842144\ \(0\)\
\-\ well\\:\\ 0\\.04359341333885715\ \(0\)\
\-\ osteosclerotic\\:\\ 0\\.04317246263183052\ \(0\)\
\-\ circumscripta\\:\\ 0\\.04317246263183052\ \(0\)\
\-\ likened\\:\\ 0\\.04317246263183052\ \(0\)\
\-\ coarsening\\:\\ 0\\.04317246263183052\ \(0\)\
\-\ obliterating\\:\\ 0\\.04317246263183052\ \(0\)\
\-\ ivory\\:\\ 0\\.04317246263183052\ \(0\)\
\-\ intensity\\:\\ 0\\.04261860438465813\ \(0\)\
\-\ grass\\:\\ 0\\.04221328020082828\ \(0\)\
\-\ weakening\\:\\ 0\\.04221328020082828\ \(0\)\
\-\ muskuloskeletal\\:\\ 0\\.04221328020082828\ \(0\)\
\-\ contradistinction\\:\\ 0\\.04140230301076154\ \(0\)\
\-\ blade\\:\\ 0\\.04069980261505984\ \(0\)\
\-\ endplates\\:\\ 0\\.04069980261505984\ \(0\)\
\-\ calcitonin\\:\\ 0\\.040080153351098206\ \(0\)\
\-\ coarsened\\:\\ 0\\.040080153351098206\ \(0\)\
\-\ flame\\:\\ 0\\.040080153351098206\ \(0\)\
\-\ manaster\\:\\ 0\\.040080153351098206\ \(0\)\
\-\ disler\\:\\ 0\\.040080153351098206\ \(0\)\
\-\ se\\:\\ 0\\.040080153351098206\ \(0\)\
\-\ archives\\:\\ 0\\.040080153351098206\ \(0\)\
\-\ afip\\:\\ 0\\.040080153351098206\ \(0\)\
\-\ frame\\:\\ 0\\.03952585819633199\ \(0\)\
\-\ body\\:\\ 0\\.03950133212406397\ \(0\)\
\-\ should\\:\\ 0\\.039163444677921315\ \(0\)\
\-\ bisphosphonates\\:\\ 0\\.03856667576532976\ \(0\)\
\-\ dg\\:\\ 0\\.03856667576532976\ \(0\)\
\-\ regard\\:\\ 0\\.038145576032087194\ \(0\)\
\-\ show\\:\\ 0\\.03810246474948849\ \(0\)\
\-\ usually\\:\\ 0\\.037785198212681226\ \(0\)\
\-\ lysis\\:\\ 0\\.037755698575263015\ \(0\)\
\-\ bj\\:\\ 0\\.037755698575263015\ \(0\)\
\-\ age\\:\\ 0\\.037681533568529\ \(0\)\
\-\ proximal\\:\\ 0\\.03749747273028839\ \(0\)\
\-\ only\\:\\ 0\\.03749747273028839\ \(0\)\
\-\ manifests\\:\\ 0\\.03739273134660191\ \(0\)\
\-\ maintenance\\:\\ 0\\.03739273134660191\ \(0\)\
\-\ company\\:\\ 0\\.03705319817956131\ \(0\)\
\-\ years\\:\\ 0\\.03679183119395334\ \(0\)\
\-\ normal\\:\\ 0\\.036759019317391374\ \(0\)\
\-\ da\\:\\ 0\\.03673425579471652\ \(0\)\
\-\ resnick\\:\\ 0\\.03643354891559968\ \(0\)\
\-\ appearance\\:\\ 0\\.03618409988748402\ \(0\)\
\-\ through\\:\\ 0\\.03572883955284099\ \(0\)\
\-\ include\\:\\ 0\\.035711716886295194\ \(0\)\
\-\ appendicular\\:\\ 0\\.035143974828345526\ \(0\)\
\-\ untreated\\:\\ 0\\.034705309342105625\ \(0\)\
\-\ osteodystrophy\\:\\ 0\\.034705309342105625\ \(0\)\
\-\ analgesics\\:\\ 0\\.03449897159658867\ \(0\)\
\-\ phases\\:\\ 0\\.03449897159658867\ \(0\)\
\-\ requisites\\:\\ 0\\.03410909413976449\ \(0\)\
\-\ inc\\:\\ 0\\.03392448087715567\ \(0\)\
\-\ osteoblastic\\:\\ 0\\.03357362168176821\ \(0\)\
\-\ unlike\\:\\ 0\\.03340659374406279\ \(0\)\
\-\ over\\:\\ 0\\.033374098304677226\ \(0\)\
\-\ begins\\:\\ 0\\.032935149721036644\ \(0\)\
\-\ yellow\\:\\ 0\\.032935149721036644\ \(0\)\
\-\ survey\\:\\ 0\\.03278694448010116\ \(0\)\
\-\ saunders\\:\\ 0\\.03278694448010116\ \(0\)\
\-\ osteoporosis\\:\\ 0\\.03197596729003441\ \(0\)\
\-\ picture\\:\\ 0\\.031497370392847\ \(0\)\
\-\ scintigraphy\\:\\ 0\\.031164990099967663\ \(0\)\
\-\ mosby\\:\\ 0\\.031164990099967663\ \(0\)\
\-\ vertebrae\\:\\ 0\\.031058704906607098\ \(0\)\
\-\ manifestations\\:\\ 0\\.03075215578576252\ \(0\)\
\-\ radiography\\:\\ 0\\.03065381763037108\ \(0\)\
\-\ spectrum\\:\\ 0\\.030462489704265964\ \(0\)\
\-\ radiographics\\:\\ 0\\.030277876441657144\ \(0\)\
\-\ case\\:\\ 0\\.030153702126865797\ \(0\)\
\-\ markings\\:\\ 0\\.030099522475604865\ \(0\)\
\-\ have\\:\\ 0\\.02998358725008116\ \(0\)\
\-\ lines\\:\\ 0\\.029927017246269682\ \(0\)\
\-\ correlation\\:\\ 0\\.029927017246269682\ \(0\)\
\-\ smith\\:\\ 0\\.0296784227423623\ \(0\)\
\-\ findings\\:\\ 0\\.029622578800993633\ \(0\)\
\-\ nsaids\\:\\ 0\\.029364243543116925\ \(0\)\
\-\ sites\\:\\ 0\\.029288545285538117\ \(0\)\
\-\ every\\:\\ 0\\.02906777423018584\ \(0\)\
\-\ subchondral\\:\\ 0\\.02871924031136007\ \(0\)\
\-\ 62\\:\\ 0\\.028586044889836418\ \(0\)\
\-\ population\\:\\ 0\\.028392368854727724\ \(0\)\
\-\ late\\:\\ 0\\.028329362854535883\ \(0\)\
\-\ always\\:\\ 0\\.028329362854535883\ \(0\)\
\-\ pulse\\:\\ 0\\.028329362854535883\ \(0\)\
\-\ exercise\\:\\ 0\\.028267102504991627\ \(0\)\
\-\ also\\:\\ 0\\.02823197510593502\ \(0\)\
\-\ radiologic\\:\\ 0\\.02796639562587479\ \(0\)\
\-\ images\\:\\ 0\\.02776352839819208\ \(0\)\
\-\ develop\\:\\ 0\\.027626862458834188\ \(0\)\
\-\ 4th\\:\\ 0\\.027626862458834188\ \(0\)\
\-\ characterized\\:\\ 0\\.02757234447733216\ \(0\)\
\-\ frequent\\:\\ 0\\.02751838566446914\ \(0\)\
\-\ unilateral\\:\\ 0\\.027464974666271597\ \(0\)\
\-\ 2nd\\:\\ 0\\.027464974666271597\ \(0\)\
\-\ destruction\\:\\ 0\\.027359752396065508\ \(0\)\
\-\ which\\:\\ 0\\.027291968844609837\ \(0\)\
\-\ skeletal\\:\\ 0\\.02720576272559162\ \(0\)\
\-\ almost\\:\\ 0\\.026958724942552283\ \(0\)\
\-\ home\\:\\ 0\\.02654133924979943\ \(0\)\
\-\ disorders\\:\\ 0\\.02649694288392265\ \(0\)\
\-\ involves\\:\\ 0\\.02611338487306574\ \(0\)\
\-\ scans\\:\\ 0\\.02611338487306574\ \(0\)\
\-\ lucency\\:\\ 0\\.02583326877614471\ \(0\)\
\-\ symmetric\\:\\ 0\\.0257176391076184\ \(0\)\
\-\ margins\\:\\ 0\\.02560449629242848\ \(0\)\
\-\ lytic\\:\\ 0\\.025278973621378494\ \(0\)\
\-\ gadolinium\\:\\ 0\\.025005616649344056\ \(0\)\
\-\ frequently\\:\\ 0\\.024714167098210036\ \(0\)\
\-\ femur\\:\\ 0\\.024620498069493103\ \(0\)\
\-\ pathologic\\:\\ 0\\.02458964203889861\ \(0\)\
\-\ deformity\\:\\ 0\\.024528467650372796\ \(0\)\
\-\ arthritis\\:\\ 0\\.02440821240006935\ \(0\)\
\-\ be\\:\\ 0\\.024347962251831147\ \(0\)\
\-\ four\\:\\ 0\\.02431979119037626\ \(0\)\
\-\ metastases\\:\\ 0\\.024261658685794794\ \(0\)\
\-\ characteristic\\:\\ 0\\.024261658685794794\ \(0\)\
\-\ oral\\:\\ 0\\.024035346884132395\ \(0\)\
\-\ sequences\\:\\ 0\\.02400773034756586\ \(0\)\
\-\ neurologic\\:\\ 0\\.02398025802333566\ \(0\)\
\-\ osseous\\:\\ 0\\.02395292841312164\ \(0\)\
\-\ references\\:\\ 0\\.023925740041833635\ \(0\)\
\-\ al\\:\\ 0\\.023845007949126192\ \(0\)\
\-\ from\\:\\ 0\\.023837641945014417\ \(0\)\
\-\ et\\:\\ 0\\.02350881400030952\ \(0\)\
\-\ pelvic\\:\\ 0\\.023458946914765477\ \(0\)\
\-\ fibrous\\:\\ 0\\.02331212050705376\ \(0\)\
\-\ extensive\\:\\ 0\\.023122516630819937\ \(0\)\
\-\ persistent\\:\\ 0\\.023122516630819937\ \(0\)\
\-\ uptake\\:\\ 0\\.02307616445313016\ \(0\)\
\-\ hip\\:\\ 0\\.02305314061710426\ \(0\)\
\-\ dysplasia\\:\\ 0\\.0229846675706601\ \(0\)\
\-\ an\\:\\ 0\\.02295168004366685\ \(0\)\
\-\ ct\\:\\ 0\\.022850410000405785\ \(0\)\
\-\ marked\\:\\ 0\\.022697836810242768\ \(0\)\
\-\ previous\\:\\ 0\\.02267640729737397\ \(0\)\
\-\ to\\:\\ 0\\.022507552150133017\ \(0\)\
\-\ pattern\\:\\ 0\\.02240548726113629\ \(0\)\
\-\ active\\:\\ 0\\.022285002496037626\ \(0\)\
\-\ radiographic\\:\\ 0\\.022265187263063414\ \(0\)\
\-\ referred\\:\\ 0\\.022206185469297028\ \(0\)\
\-\ commonly\\:\\ 0\\.022206185469297028\ \(0\)\
\-\ its\\:\\ 0\\.022206185469297028\ \(0\)\
\-\ abnormalities\\:\\ 0\\.021738654379240534\ \(0\)\
\-\ heterogeneous\\:\\ 0\\.02172079039557306\ \(0\)\
\-\ early\\:\\ 0\\.02163236918587997\ \(0\)\
\-\ ap\\:\\ 0\\.021545409550896986\ \(0\)\
\-\ typically\\:\\ 0\\.021067562662711512\ \(0\)\
\-\ or\\:\\ 0\\.02088010169914279\ \(0\)\
\-\ side\\:\\ 0\\.020731968798090215\ \(0\)\
\-\ asymptomatic\\:\\ 0\\.020430440987687454\ \(0\)\
\-\ inferior\\:\\ 0\\.02041650471957721\ \(0\)\
\-\ available\\:\\ 0\\.020361125912067336\ \(0\)\
\-\ extending\\:\\ 0\\.020347371817605344\ \(0\)\
\-\ flow\\:\\ 0\\.019988985292877674\ \(0\)\
\-\ joint\\:\\ 0\\.019775249929828004\ \(0\)\
\-\ patient\\:\\ 0\\.01952169154522473\ \(0\)\
\-\ superior\\:\\ 0\\.01951094631903086\ \(0\)\
\-\ mr\\:\\ 0\\.019418035504512342\ \(0\)\
\-\ approximately\\:\\ 0\\.019148760282461947\ \(0\)\
\-\ t1\\:\\ 0\\.01869829553641455\ \(0\)\
\-\ treated\\:\\ 0\\.018688265146083145\ \(0\)\
\-\ renal\\:\\ 0\\.018688265146083145\ \(0\)\
\-\ decreased\\:\\ 0\\.018588999217453224\ \(0\)\
\-\ demonstrated\\:\\ 0\\.018443526221780488\ \(0\)\
\-\ loss\\:\\ 0\\.01828337786984713\ \(0\)\
\-\ for\\:\\ 0\\.01819178645241193\ \(0\)\
\-\ when\\:\\ 0\\.01812796092369027\ \(0\)\
\-\ abnormal\\:\\ 0\\.018029789594197754\ \(0\)\
\-\ focal\\:\\ 0\\.017950808222201988\ \(0\)\
\-\ shows\\:\\ 0\\.0176134530465546\ \(0\)\
\-\ months\\:\\ 0\\.017468425660222043\ \(0\)\
\-\ blood\\:\\ 0\\.017428839783945785\ \(0\)\
\-\ axial\\:\\ 0\\.017335031566538286\ \(0\)\
\-\ enhancement\\:\\ 0\\.01727340933187566\ \(0\)\
\-\ t2\\:\\ 0\\.017265757056875327\ \(0\)\
\-\ therapy\\:\\ 0\\.017242866789573905\ \(0\)\
\-\ low\\:\\ 0\\.017220075686196188\ \(0\)\
\-\ high\\:\\ 0\\.017055891242732685\ \(0\)\
\-\ fracture\\:\\ 0\\.017055891242732685\ \(0\)\
\-\ common\\:\\ 0\\.01701928053037199\ \(0\)\
\-\ metastatic\\:\\ 0\\.01645915123235728\ \(0\)\
\-\ symptoms\\:\\ 0\\.016419939089569933\ \(0\)\
\-\ physical\\:\\ 0\\.016272276465120434\ \(0\)\
\-\ soft\\:\\ 0\\.015976847943158703\ \(0\)\
\-\ associated\\:\\ 0\\.01581768137247191\ \(0\)\
\-\ imaging\\:\\ 0\\.015771431069013814\ \(0\)\
\-\ tissue\\:\\ 0\\.01574272975322752\ \(0\)\
\-\ woman\\:\\ 0\\.01562946513873596\ \(0\)\
\-\ other\\:\\ 0\\.015584833370435949\ \(0\)\
\-\ diagnosis\\:\\ 0\\.015557129577427073\ \(0\)\
\-\ mri\\:\\ 0\\.015404627939245718\ \(0\)\
\-\ present\\:\\ 0\\.01539926237209508\ \(0\)\
\-\ it\\:\\ 0\\.015361855848890547\ \(0\)\
\-\ demonstrates\\:\\ 0\\.015076851063432898\ \(0\)\
\-\ treatment\\:\\ 0\\.014295500826678773\ \(0\)\
\-\ within\\:\\ 0\\.013821821224723519\ \(0\)\
\-\ has\\:\\ 0\\.013707833048045884\ \(0\)\
\-\ by\\:\\ 0\\.01274411616291251\ \(0\)\
\-\ not\\:\\ 0\\.011847354674202767\ \(0\)\
\-\ mass\\:\\ 0\\.011463135504345301\ \(0\)\
\-\ was\\:\\ 0\\.010458888523653424\ \(0\)\
